Observational studyClinical rheumatology2026
Factors associated with discontinuation of bDMARDs and JAK inhibitors in patients with rheumatoid arthritis: a retrospective study.
Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesTo compare the discontinuation rates of different biologic agents and Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA) and identify the reasons and associated factors for discontinuation.
methodIn this retrospective observational study, data were retrospectively collected from patients with RA who were treated with biological agents and JAK inhibitors at the Rheumatology and Immunology Department of Taizhou Hospital of Zhejiang Province between January 2021 and March 2024. Reasons for discontinuation were categorized, and factors associated with drug discontinuation and retention were assessed.
resultsAnalysis of 242 treatment records (from 218 patients) revealed an overall treatment discontinuation rate of 43.4%. The median follow-up was 21.4 months (interquartile range [IQR], 12.0-35.5). JAK inhibitors, specifically tofacitinib, were associated with significantly superior drug retention compared to TNF inhibitors and tocilizumab. Although elevated pretreatment inflammatory markers-white blood cell (WBC) counts and C-reactive protein (CRP) were associated with discontinuation in univariate analysis, this association was not significant after adjusting for other variables. Multivariable logistic regression identified lack of medical insurance as an independent risk factor for discontinuation, while JAK inhibitor usage was an independent protective factor. The finding of superior retention for JAK inhibitors was confirmed in a propensity score-matched analysis.
conclusionsIn conclusion, our findings highlight lack of insurance, male sex and drug class as key factors associated with treatment discontinuation in routine care, with tofacitinib showing promising retention. These real-world predictors merit consideration in patient management while acknowledging that observational data supports hypothesis generation for future interventional studies. Key Points • JAK inhibitor use (particularly tofacitinib) was an independent protective factor, associated with superior drug retention compared to other classes. • Socioeconomic factors (insurance and cost) outweighed baseline inflammatory markers as predictors of treatment persistence in the real-world setting.
Indexed as
Identifiers
42587227What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.